{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T22:32:08Z","timestamp":1791844328358,"version":"4.3.4"},"reference-count":38,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background: Patients with rheumatic diseases (RMDs) are at increased risk of herpes zoster (HZ), particularly when receiving immunosuppressive treatment. While recombinant zoster vaccine (RZV) has shown high effectiveness in the general population, evidence in rheumatologic patients remain limited due to their exclusion from pivotal trials. Objectives: To evaluate the effectiveness of RZV and to collect additional safety data in a heterogeneous cohort of rheumatologic patients, compared with a control cohort from the general population. Methods: We conducted a retrospective study including 179 adults who received two intramuscular doses of RZV between January 2021 and June 2025. The cohort included 114 patients with RMDs and 65 individuals from the general population. Effectiveness was defined as the ability to prevent HZ reactivation while safety concerns were recorded as any adverse event temporally associated with the vaccination. Results: We observed a statistically significant reduction in terms of VZV relapses following vaccination (p &lt; 0.001). Among patients diagnosed with RMDs, only one case of HZ recurrence was observed 14 weeks after vaccination, with no significant difference compared to general care patients. One patient experienced a disease flare requiring glucocorticosteroids. RZV demonstrated a favourable safety profile, with minor adverse events (fever, injection-site reactions, headache and myalgia) reported in 17.5% of patients after the first dose and 21.5% after the second. No significant association was observed between adverse events and advanced immunosuppressive therapy. Conclusions: RZV displayed an effective and reassuring safety profile in a heterogeneous cohort of patients affected by RMDs, irrespective of the diagnosis and the ongoing therapy. This supports the broader use of RZV as a safe and valuable preventive strategy in patients with RMDs.<\/jats:p>","DOI":"10.3390\/vaccines13121227","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T10:50:38Z","timestamp":1764931838000},"page":"1227","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Effectiveness and Safety of Recombinant Zoster Vaccine in Rheumatic Diseases: Real-World Evidence from a Single-Centre Italian Cohort"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3897-7226","authenticated-orcid":false,"given":"Silvia","family":"Valentini","sequence":"first","affiliation":[{"name":"Rheumatology Unit Department of Medicine, Surgery and Neurosciences, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurgen","family":"Sota","sequence":"additional","affiliation":[{"name":"Rheumatology Unit Department of Medicine, Surgery and Neurosciences, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Fineschi","sequence":"additional","affiliation":[{"name":"Usl Sud-Est Tuscany, 52100 Arezzo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3974-6606","authenticated-orcid":false,"given":"Edoardo","family":"Conticini","sequence":"additional","affiliation":[{"name":"Rheumatology Unit Department of Medicine, Surgery and Neurosciences, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5906-4891","authenticated-orcid":false,"given":"Estrella","family":"Garcia-Gonzalez","sequence":"additional","affiliation":[{"name":"Rheumatology Unit Department of Medicine, Surgery and Neurosciences, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"D\u2019Ignazio","sequence":"additional","affiliation":[{"name":"Rheumatology Unit Department of Medicine, Surgery and Neurosciences, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1893-0401","authenticated-orcid":false,"given":"Marco","family":"Bardelli","sequence":"additional","affiliation":[{"name":"Rheumatology Unit Department of Medicine, Surgery and Neurosciences, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6658-1037","authenticated-orcid":false,"given":"Stefano","family":"Gentileschi","sequence":"additional","affiliation":[{"name":"Rheumatology Unit Department of Medicine, Surgery and Neurosciences, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Fabbroni","sequence":"additional","affiliation":[{"name":"Rheumatology Unit Department of Medicine, Surgery and Neurosciences, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bellisai","sequence":"additional","affiliation":[{"name":"Rheumatology Unit Department of Medicine, Surgery and Neurosciences, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2667-4866","authenticated-orcid":false,"given":"Paolo","family":"Falsetti","sequence":"additional","affiliation":[{"name":"Rheumatology Unit Department of Medicine, Surgery and Neurosciences, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Selvi","sequence":"additional","affiliation":[{"name":"Rheumatology Unit Department of Medicine, Surgery and Neurosciences, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7352-1275","authenticated-orcid":false,"given":"Luca","family":"Cantarini","sequence":"additional","affiliation":[{"name":"Rheumatology Unit Department of Medicine, Surgery and Neurosciences, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Frediani","sequence":"additional","affiliation":[{"name":"Rheumatology Unit Department of Medicine, Surgery and Neurosciences, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3070-5568","authenticated-orcid":false,"given":"Caterina","family":"Baldi","sequence":"additional","affiliation":[{"name":"Rheumatology Unit Department of Medicine, Surgery and Neurosciences, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1080\/21645515.2020.1847582","article-title":"A systematic literature review of herpes zoster incidence worldwide","volume":"17","year":"2021","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"ofaa005","DOI":"10.1093\/ofid\/ofaa005","article-title":"Risk Factors for Herpes Zoster Infection: A Meta-Analysis","volume":"7","author":"Marra","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e022897","DOI":"10.1136\/bmjopen-2018-022897","article-title":"Association between statin use and herpes zoster: Systematic review and meta-analysis","volume":"9","author":"Fan","year":"2019","journal-title":"BMJ Open"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s40267-024-01126-0","article-title":"Expanding the coverage of herpes zoster vaccination recommendations in European countries: The example of Portugal","volume":"41","author":"Duque","year":"2025","journal-title":"Drugs Ther. Perspect."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e000935","DOI":"10.1136\/rmdopen-2019-000935","article-title":"Serious infection risk in rheumatoid arthritis compared with non-inflammatory rheumatic and musculoskeletal diseases: A US national cohort study","volume":"5","author":"Mehta","year":"2019","journal-title":"RMD Open"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1479-5876-12-77","article-title":"Infection risk in rheumatoid arthritis and spondyloarthropathy patients under treatment with DMARDs, corticosteroids and TNF-\u03b1 antagonists","volume":"12","author":"Germano","year":"2014","journal-title":"J. Transl. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.reumae.2021.06.001","article-title":"JAK kinase inhibitors and varicella zoster virus infection in patients with rheumatoid arthritis. Systematic review of the literature","volume":"18","year":"2022","journal-title":"Reumatol. Cl\u00edn. (Engl. Ed.)"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","article-title":"2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases","volume":"79","author":"Furer","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/acr.25045","article-title":"2022 American College of Rheumatology guideline for vaccinations in patients with rheumatic and musculoskeletal diseases","volume":"75","author":"Bass","year":"2023","journal-title":"Arthritis Care Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"S429","DOI":"10.1093\/infdis\/jiab387","article-title":"Herpes zoster vaccines","volume":"224","author":"Harbecke","year":"2021","journal-title":"J. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1016\/j.vaccine.2019.04.014","article-title":"The comparative efficacy and safety of herpes zoster vaccines: A network meta-analysis","volume":"37","author":"McGirr","year":"2019","journal-title":"Vaccine"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1093\/rheumatology\/keaa424","article-title":"Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: A pooled post hoc analysis on two parallel randomized trials","volume":"60","author":"Dagnew","year":"2021","journal-title":"Rheumatology"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Xia, Y., Zhang, X., Zhang, L., and Fu, C. (2022). Efficacy, effectiveness, and safety of herpes zoster vaccine in the immunocompetent and immunocompromised subjects: A systematic review and network meta-analysis. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.978203"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"5149","DOI":"10.1093\/rheumatology\/keab139","article-title":"Safety of recombinant zoster vaccine: A retrospective study of 622 rheumatology patients","volume":"60","author":"Lenfant","year":"2021","journal-title":"Rheumatology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"152515","DOI":"10.1016\/j.semarthrit.2024.152515","article-title":"Risk of incident gout following exposure to recombinant zoster vaccine in US adults aged \u2265 65 years","volume":"68","author":"Zhang","year":"2024","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Cito, A., Fornaro, M., Carenza, A., Anelli, M.G., Scioscia, C., Iannone, F., and Lopalco, G. (2024). Turning the tide against herpes zoster in rheumatoid arthritis patients treated with JAK inhibitors. J. Clin. Med., 13.","DOI":"10.3390\/jcm13154423"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1007\/s10067-024-07041-z","article-title":"Prior herpes zoster occurrence and high-dose corticosteroids increase herpes zoster risk in rheumatoid arthritis patients receiving janus kinase inhibitors in a retrospective and observational study","volume":"43","author":"Chen","year":"2024","journal-title":"Clin. Rheumatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/cid\/ciz177","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in chronically immunosuppressed adults following renal transplant: A phase 3, randomized clinical trial","volume":"70","author":"Vink","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S1473-3099(19)30163-X","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: A phase 3, randomised, clinical trial and post-hoc efficacy analysis","volume":"19","author":"Dagnew","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e247","DOI":"10.1016\/S2665-9913(24)00019-5","article-title":"Time to talk to adults with rheumatic diseases about herpes zoster vaccination","volume":"6","author":"Pier","year":"2024","journal-title":"Lancet Rheumatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"rxaf012","DOI":"10.1093\/mrcr\/rxaf012","article-title":"Breakthrough herpes zoster following recombinant zoster vaccinations in a rheumatoid arthritis patient receiving a Janus kinase inhibitor: A case report and literature review","volume":"9","author":"Nagata","year":"2025","journal-title":"Mod. Rheumatol. Case Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/acr2.11150","article-title":"Safety of the zoster vaccine recombinant adjuvanted in rheumatoid arthritis and other systemic rheumatic disease patients: A single center\u2019s experience with 400 patients","volume":"2","author":"Stevens","year":"2020","journal-title":"ACR Open Rheumatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1093\/rheumatology\/kead552","article-title":"Serologic immunogenicity and safety of herpes zoster subunit vaccine in patients with rheumatoid arthritis receiving Janus kinase inhibitors","volume":"63","author":"Nagel","year":"2024","journal-title":"Rheumatology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1136\/annrheumdis-2023-eular.1013","article-title":"AB1774-HPR safety of the recombinant herpes zoster vaccine in patients with rheumatoid arthritis treated with jaki drugs","volume":"82","author":"Rosas","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e003902","DOI":"10.1136\/rmdopen-2023-003902","article-title":"Immunogenicity and influence on disease activity of recombinant zoster vaccine in patients with rheumatoid arthritis treated with DMARDs","volume":"10","author":"Kojima","year":"2024","journal-title":"RMD Open"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"125","DOI":"10.14423\/SMJ.0000000000001354","article-title":"Safety of Recombinant Zoster Vaccine in Rheumatology Patients","volume":"115","author":"Raza","year":"2022","journal-title":"South. Med. J."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Venerito, V., Stefanizzi, P., Cantarini, L., Lavista, M., Galeone, M.G., Di Lorenzo, A., Iannone, F., Tafuri, S., and Lopalco, G. (2023). Immunogenicity and safety of adjuvanted recombinant zoster vaccine in rheumatoid arthritis patients on anti-cellular biologic agents or JAK inhibitors: A prospective observational study. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24086967"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13075-025-03565-0","article-title":"Real-world data on the use of the Shingrix vaccine among patients with inflammatory arthritis and risk of cardiovascular events following herpes zoster","volume":"27","author":"Curtis","year":"2025","journal-title":"Arthritis Res. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1016\/j.vaccine.2024.03.024","article-title":"Safety profile of recombinant adjuvanted anti-herpes zoster vaccine (RZV) in high-risk groups: Data from active surveillance program. Puglia (Italy), 2021\u20132023","volume":"42","author":"Stefanizzi","year":"2024","journal-title":"Vaccine"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Esteban-Vazquez, A., Steiner, M., Casta\u00f1eda, E., Andreu-Vazquez, C., Thiussard, I.J., Somodevilla, A., Gracia-Mart\u00ednez, M., S\u00e1nchez-Diaz, R., Garc\u00eda-Yubero, C., and Paredes-Romero, M.B. (2023). The real-world study of immunogenicity and safety of the adjuvant recombinant vaccine against varicella zoster virus in patients with immune-mediated inflammatory diseases treated with Janus kinase inhibitors. Vaccines, 11.","DOI":"10.3390\/vaccines11101610"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1093\/rheumatology\/keae584","article-title":"Immunogenicity to Herpes Zoster recombinant subunit vaccine in immune-mediated rheumatic patients under treatment with JAK inhibitors","volume":"64","author":"Herrero","year":"2025","journal-title":"Rheumatology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1136\/annrheumdis-2014-207191","article-title":"The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis","volume":"75","author":"Winthrop","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1136\/annrheumdis-2021-221244","article-title":"Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases","volume":"80","author":"Friedman","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Watanabe, R., Fujii, H., Imai, T., Furusawa, Y., Katsushima, M., Fukumoto, K., Yamada, Y., Mamoto, K., Okano, T., and Yamada, S. (2024). Immune Response to an Adjuvanted Recombinant Zoster Vaccine in Japanese Patients with Rheumatoid Arthritis Receiving Upadacitinib (End Zoster-J Study): Study Protocol for an Exploratory Parallel Triple-Arm Prospective Trial. J. Clin. Med., 13.","DOI":"10.21203\/rs.3.rs-5097927\/v1"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e090668","DOI":"10.1136\/bmjopen-2024-090668","article-title":"Optimal timing of recombinant herpes zoster virus vaccination for a JAK inhibitor treatment in rheumatoid arthritis: A multicentre, open-label, randomised comparative study (STOP-HZ study): Study protocol","volume":"14","author":"Takanashi","year":"2024","journal-title":"BMJ Open"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1097\/RHU.0000000000002216","article-title":"Disease Safety, Immunogenicity, and Efficacy of Recombinant Herpes Zoster Vaccine (RZV or Shingrix) in Autoimmune Rheumatic Diseases: Launching a Randomized Phase 4 Study","volume":"31","author":"Kupa","year":"2025","journal-title":"JCR J. Clin. Rheumatol."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/12\/1227\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T12:25:58Z","timestamp":1764937558000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/12\/1227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":38,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["vaccines13121227"],"URL":"https:\/\/doi.org\/10.3390\/vaccines13121227","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]}}}